Prosecution Insights
Last updated: November 04, 2026
Application No. 18/712,073

A PROCESS TO TREAT A CARBON DIOXIDE COMPRISING GAS

Final Rejection §DOUBLEPATENT
Filed
May 21, 2024
Priority
Nov 26, 2021 — NL 2029926 +1 more
Examiner
BERKE-SCHLESSEL, DAVID W
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Paqell B V
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
5m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
508 granted / 759 resolved
+6.9% vs TC avg
Strong +31% interview lift
Without
With
+31.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
41 currently pending
Career history
816
Total Applications
across all art units

Statute-Specific Performance

§101
9.6%
-30.4% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 759 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments The Applicant has provided a response, dated 8/25/2026. In the response, the Applicant provided amendments to the claims, new claims 17-20, and arguments drawn to the previous rejections and objections. Based upon the claim amendments, the objections to claims 1 and 12 are withdrawn. Additionally, the provided amendments allow for the withdrawal of the 35 USC 112(a) and 112(b) rejections. When considering the claim amendments in terms of the non-statutory double patenting rejection, most of the claims continue to be considered non-statutory double patenting; however, under closer consideration, claims 16-20 would be allowable, but must be objected to because they are dependent on rejected claims. As such, the non-statutory double patenting rejection is maintained for the reasons provided previously. Claims 16-20 are not rejected because there is nothing in the cited patent, or prior art that would make it obvious to modify the Liu patent with a halophilic methanogen. Claims 1-15 are rejected as being considered non-statutory double patenting with US Pat. 12,624,371. Claims 16-20 are allowable, but must be objected to, since they are dependent on rejected claims. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 12,624,371. Although the claims at issue are not identical, they are not patentably distinct from each other because both the patent and the instant claim-set provide for methods with overlapping limitations and scope. The patent is drawn to a method of converting carbon dioxide to methane by creating a “charged pack bed” with biofilm, under aerobic conditions, while utilizing a specifically claimed salt concentration and dissolved carbon dioxide concentration. Similar to the patent, the instant claims provide for a method of converting carbon dioxide to methane by creating a “charged pack bed” with biofilm, under aerobic conditions, while utilizing a specifically claimed salt concentration, pH range, and phosphate level. In addition to the general method steps, which are identical, the patent and the instant claim-set provide for identical cation concentrations. The main difference between the claim-sets is that the patent clearly defines how the dissolved carbon dioxide is received, whereas the instant claim-set does not describe this value; additionally, the instant independent claim provides for a specific pH, which is described in a dependent claim in the patent (claims 14 and 19). When looking at the limitations provided in the patent, the patent’s claim-set is broader than the instant claim-set. However, all of the limitations found in the instant claim-set would necessarily fall within the scope provided in the patent. The only major unclaimed difference between the patent and the instant claim-set is that the instant claim-set provides for a lower-limit for the phosphate concentration. When considering this limitation against the patent, it is noted that the applied example specifically utilizes a phosphate buffer saline with 50 mM phosphate, which would include the claimed range. Since the claims of the patent anticipate the claims of the instant claim-set, and the cited differences do not appear to provide for any unexpected improvements, the instant claim-set is considered non-statutory double patenting with the cited patent. Allowable Subject Matter Claims 16-20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID W BERKE-SCHLESSEL whose telephone number is (571)270-3643. The examiner can normally be reached M-F 8AM-5:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAVID W BERKE-SCHLESSEL/Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

May 21, 2024
Application Filed
Jun 04, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Aug 25, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767971
METHOD TO PRODUCE RETINYL ACETATE
2y 8m to grant Granted Oct 20, 2026
Patent 12767969
ENZYME COMPOSITION FOR PREPARING Beta-NICOTINAMIDE MONONUCLEOTIDE, AND APPLICATION THEREOF
3y 0m to grant Granted Oct 20, 2026
Patent 12761209
Devices and Methods to Induce Adult type Maturation of Human Pluripotent Stem Cell Derived Cardiomyocytes
3y 7m to grant Granted Oct 13, 2026
Patent 12761210
PREDICTING EFFICACY OF OR RESISTANCE TO TREATMENT OF COLON CANCER
3y 3m to grant Granted Oct 13, 2026
Patent 12761208
IPSC-DERIVED ASTROCYTES AND METHODS OF USE THEREOF
3y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
98%
With Interview (+31.3%)
2y 10m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 759 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month